Journal
ANTI-CANCER DRUGS
Volume 17, Issue 1, Pages 13-20Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.cad.0000185180.72604.ac
Keywords
angiogenesis; cancer; cell motility; Grb2; growth factor receptor-bound 2; metastasis
Categories
Funding
- Intramural NIH HHS Funding Source: Medline
- NATIONAL CANCER INSTITUTE [Z01SC006659, ZIABC006198, Z01BC006198] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Growth factor receptor-bound 2 (Grb2) is a ubiquitously expressed adapter protein that provides a critical link between cell surface growth factor receptors and the Ras signaling pathway. As such, it has been implicated in the oncogenesis of several important human malignancies. In addition to this function, research over the last decade has revealed other fundamental roles for Grb2 in cell motility and angiogenesis-processes that also contribute to tumor growth, invasiveness and metastasis. This functional profile makes Grb2 a high priority target for anti-cancer drug development. Knowledge of Grb2 protein structure, its component Src homology domains and their respective structure-function relationships has facilitated the rapid development of sophisticated drug candidates that can penetrate cells, bind Grb2 with high affinity and potently antagonize Grb2 signaling. These novel compounds offer considerable promise in our growing arsenal of rationally designed anti-cancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available